User profiles for Keyur Parikh
 | Keyur ParikhCare Institute of Medical Sciences Verified email at cims.org Cited by 3329 |
[HTML][HTML] Platelet inhibition with cangrelor in patients undergoing PCI
…, WJ French, F Leisch, KH Parikh… - … England Journal of …, 2009 - Mass Medical Soc
Background Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an intravenous
blocker of the adenosine diphosphate receptor P2Y 12 . This agent might have a role …
blocker of the adenosine diphosphate receptor P2Y 12 . This agent might have a role …
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial
Background—Reduced renal function is associated with a poorer prognosis and increased
bleeding risk in patients with acute coronary syndromes and may therefore alter the risk-…
bleeding risk in patients with acute coronary syndromes and may therefore alter the risk-…
Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial
Background— Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no
cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment …
cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment …
Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial
J Hiremath, S Thanikachalam, K Parikh… - The Journal of heart and …, 2010 - Elsevier
BACKGROUND: Pulmonary arterial hypertension (PAH) remains a poorly understood and
frequently lethal disease with few treatment options. METHODS: We conducted a placebo-…
frequently lethal disease with few treatment options. METHODS: We conducted a placebo-…
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label …
Background We sought to compare the long-term safety of two devices with different
antiproliferative properties: the Endeavor zotarolimus-eluting stent (E-ZES; Medtronic, Inc) and the …
antiproliferative properties: the Endeavor zotarolimus-eluting stent (E-ZES; Medtronic, Inc) and the …
Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study
S Banai, S Ben Muvhar, KH Parikh, A Medina… - Journal of the American …, 2007 - jacc.org
Objectives : This study sought to evaluate the safety of the Coronary Sinus Reducer (Neovasc
Medical, Inc., Or Yehuda, Israel) as a potential alternate therapy for patients with refractory …
Medical, Inc., Or Yehuda, Israel) as a potential alternate therapy for patients with refractory …
Safety and feasibility of orbital atherectomy for the treatment of calcified coronary lesions: the ORBIT I trial
K Parikh, P Chandra, N Choksi… - Catheterization and …, 2013 - Wiley Online Library
Objective: The ORBIT I trial evaluated the safety and performance of an orbital atherectomy
system (OAS) for the treatment of de novo calcified coronary lesions. Background: Severely …
system (OAS) for the treatment of de novo calcified coronary lesions. Background: Severely …
Unusual causes of upper gastrointestinal bleeding
K Parikh, MA Ali, RCK Wong - Gastrointestinal Endoscopy …, 2015 - giendo.theclinics.com
Initially described by Philemon Truesdale in 1924 1 and then further expanded on in a case
series published by Cameron in 1976, 2 Cameron lesions are best described as linear …
series published by Cameron in 1976, 2 Cameron lesions are best described as linear …
Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the …
Aims To compare the long-term clinical safety between two drug-eluting stents with different
healing characteristics in the Patient Related Outcomes with Endeavour (E-ZES) vs. Cypher (…
healing characteristics in the Patient Related Outcomes with Endeavour (E-ZES) vs. Cypher (…
[HTML][HTML] Safety and efficacy of myval implantation in patients with severe bicuspid aortic valve stenosis—a multicenter real-world experience
…, A Ielasi, SK Dora, S Chandra, K Parikh… - Journal of Clinical …, 2022 - mdpi.com
Bicuspid aortic valve (BAV) is the most common valvular congenital anomaly and is
apparent in nearly 50% of candidates for AV replacement. While transcatheter aortic valve …
apparent in nearly 50% of candidates for AV replacement. While transcatheter aortic valve …